A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors

A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06650808 IN PATIENTS WITH ADVANCED SOLID TUMORS

To assess the safety and tolerability at increasing dose levels of PF-06650808 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Inclusion Criteria:

• Diagnosis of advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available
• Previously treated metastatic triple negative breast cancer that expresses Notch3 with at least one measurable lesion
• Adequate bone marrow, renal and liver function

Exclusion Criteria:

• Major surgery, radiation therapy or systemic anti-cancer therapy within 4 weeks of starting study treatment
• Patients with known symptomatic brain metastases requiring steroids
• Prior treatment with a compound of the same mechanism